internal
Robert A. Bradway
Chairman, Chief Executive Officer and President
Executive
13 yr
30 reports
Amgen Inc. ·AMGN
No COO — science, markets, and finance report directly to CEO
Health Care · Fortune #134 · Divisional structure · 28K employees · Thousand Oaks, CA
View as of:
5
CEO span
↓ tighter than peers (avg 10)
2.6
Avg span
moderate
3
Max depth
3 levels
7 yr
Avg tenure
stable vs FY2024
80%
Internal hires
↑ above industry avg
Consolidated financials FY2025 · period end 2025-12-31 · 10-K
Revenue
$36.8B
Operating income
$9.1B
Net income
$7.7B
Total assets
$90.6B
Shares out
539M
Sourced from Amgen Inc. DEF 14A · filed 2026-04-07 ↗ View on SEC
Interactive org chart
Amgen Inc. organizational chart
Explore the executive structure, reporting layers, and scenario-ready operating model from public filings.
Open editable chart
Take this model into your AI workspace Use AI to reason through the model, then bring the scenario back into Creately Atlas.
Choose a prompt, then open an AI app and paste.
Download the CSV data instead
No COO at Amgen: research, commercial, finance, technology, and legal leaders report directly to CEO Robert Bradway. This page maps Amgen’s divisional leadership, analyzes its CEO-centric structure, recent tech reorganization, and compares it with peer pharma companies.
What to model
Use the chart to test org decisions, not just view reporting lines
Start with the public baseline, then use the scenario views and source-backed changes to ask what happens when leadership, span, or team ownership shifts.
Latest signal David M. Reese departed as EVP and Chief Technology Officer
Announced retirement effective June 30, 2026; responsibilities redistributed effective June 1, 2026.
Source · See change logScenario views in the chart
- Add Chief AI Officer Create a dedicated Chief AI Officer reporting to the CEO to centralize advanced analytics and AI governance.
- CTO Retirement Completed Finalize removal of the CTO role after June 2026 with all technology teams reassigned.
Atlas work this supports
- Connect Workday or UKG Get these analytics for YOUR org — tenure, span of control, headcount, automatically from your HRIS.
- Connect Salesforce Map your target accounts like this. Import contacts, visualize decision chains, plan multi-threading.
- Plan a Reorg Use this as a starting point. Model scenarios, compare structures, present options to your board.
The people
Who's running this
6 executives identified as Named Executive Officers in the most recent SEC proxy. Bar length scales with tenure.
James E. Bradner
Executive Vice President, Research and Development, Artificial Intelligence and Data
R&D
2 yr
12 reports
internal
Peter H. Griffith
Executive Vice President and Chief Financial Officer
Finance
5 yr
10 reports
internal
Murdo Gordon
Executive Vice President, Global Commercial Operations
Commercial
8 yr
11 reports
internal
David M. Reese
Executive Vice President and Chief Technology Officer
Technology
7 yr
5 reports
internal
Jonathan P. Graham
Executive Vice President, General Counsel and Secretary
Legal
6 yr
4 reports
The pay
Executive compensation
From the most recent DEF 14A Summary Compensation Table. 1 named executive officers disclosed. Bar length scales with total compensation.
Robert A. Bradway $24.7M
- Base salary
- $1.93M
- Stock awards
- $12.60M
- Option awards
- $5.40M
- Non-equity incentive
- $3.91M
- Other
- $861K
- Fiscal year
- FY2025
- Source
- SEC DEF 14A ↗
The skin in the game
Beneficial ownership
Insider stock holdings and the company's ownership requirements for executives and directors. Disclosed in the most recent DEF 14A.
Stock ownership requirements
6×CEO base salary
3×NEO base salary
5×Director cash retainer
Stock ownership guidelines require executives and directors to hold multiples of base salary or retainer.
| Holder | Shares | % of class |
|---|---|---|
| Robert A. Bradway | 1.47M | <1% |
The businesses
How Amgen Inc. divides the work
5 divisions report into the group CEO. Tile size scales with estimated headcount.
Research & Development
8K employees
EVP, Research and Development (James E. Bradner)
Responsible for discovery, development, and clinical advancement of Amgen’s pipeline.
Global Commercial
7K employees
EVP, Global Commercial Operations (Murdo Gordon)
Leads global sales, marketing, access, and policy for Amgen’s marketed products.
Finance
2K employees
EVP & CFO (Peter H. Griffith)
Oversees financial strategy, accounting, treasury, and investor relations.
Technology
2K employees
EVP & CTO (David M. Reese)
Manages enterprise technology, data platforms, and digital capabilities.
Legal & Compliance
500 employees
EVP, General Counsel (Jonathan P. Graham)
Handles legal affairs, compliance, governance, and regulatory risk.
The thesis
Why this org is unusual
Amgen operates without a Chief Operating Officer, leaving science, global markets, and finance as parallel power centers reporting directly to the CEO.
This structure concentrates decision rights at the top while preserving autonomy across R&D and commercial divisions. The April 2026 decision to retire the CTO role and redistribute technology responsibilities further reinforces a functional-divisional hybrid centered on scientific leadership.
- No COO
- CTO role retired in 2026
- CEO is also Board Chair
The comparison
How Amgen Inc. stacks up
Compared with large pharma peers, Amgen’s structure is notably CEO-centric and flatter at the top. Companies like Pfizer and Johnson & Johnson employ COOs or segment CEOs to buffer the CEO, while Amgen keeps direct oversight of R&D, commercial, and finance. This places heavier coordination demands on the CEO …
C-suite size
Reporting depth
Amgen Inc.
3 levels
5 levels
Johnson & Johnson
6 levels
5 levels
5 levels
4 levels
Avg C-suite tenure
Amgen Inc.
7 yr
6 yr
Johnson & Johnson
7 yr
6 yr
6 yr
Has COO / Has CAIO
Amgen Inc. — no COO — no CAIO
Johnson & Johnson ✓ COO — no CAIO
Current signals
What changed recently
Amgen is eliminating the standalone CTO role in mid‑2026, redistributing technology responsibilities across R&D, commercial, and finance leadership.
- departedDavid M. Reese EVP and Chief Technology Officer
Announced retirement effective June 30, 2026; responsibilities redistributed effective June 1, 2026.
Source - reorgJames E. Bradner EVP, Research and Development, AI and Data
Expanded remit to include AI and data responsibilities following CTO retirement announcement (June 1, 2026).
Source
Leadership Timeline
Year-over-year executive structure based on SEC proxy and annual filings.
FY2025
DEF 14A filed 2026-04-07
- CEO
- Robert A. Bradway
- CEO span
- 5
- C-suite
- 5
- Avg tenure
- 7.2 yr
Stable CEO-led structure with technology still centralized under a CTO.
Named executive officers (5)
- Robert A. Bradway - CEO since 2011
- Peter H. Griffith - CFO since 2020
- Murdo Gordon - EVP, Global Commercial since 2017
- David M. Reese - EVP & CTO since 2019
- James E. Bradner - EVP, R&D since 2023
FY2024
DEF 14A filed 2025-04-09
- CEO
- Robert A. Bradway
- CEO span
- 5
- C-suite
- 5
- Avg tenure
- 6.8 yr
R&D strengthened with external hire of James Bradner.
Named executive officers (5)
- Robert A. Bradway - CEO since 2011
- Peter H. Griffith - CFO since 2020
- Murdo Gordon - EVP, Global Commercial since 2017
- David M. Reese - EVP & CTO since 2019
- James E. Bradner - EVP, R&D since 2023
FY2023
DEF 14A filed 2024-04-17
- CEO
- Robert A. Bradway
- CEO span
- 4
- C-suite
- 4
- Avg tenure
- 7.5 yr
Lean executive team prior to R&D expansion.
Named executive officers (4)
- Robert A. Bradway - CEO since 2011
- Peter H. Griffith - CFO since 2020
- Murdo Gordon - EVP, Global Commercial since 2017
- David M. Reese - EVP & CTO since 2019
Year-over-year changes
Amgen added a dedicated R&D leader, expanding the CEO’s span of control.
- CEO span: 4 → 5
- C-suite size: 4 → 5
- Avg tenure: 6.8 → 7.2 yr
- new James E. Bradner - EVP, Research and Development (DEF 14A, Apr 2025)
CTO retirement prompted redistribution of technology oversight without adding a COO or new C-suite role.
- CEO span: 5 → 5
- C-suite size: 5 → 5
- Avg tenure: 7.2 → 7 yr
- departed David M. Reese - EVP & CTO (was EVP & CTO) (8-K, Apr 22 2026)
- reorg Technology Function - CTO responsibilities redistributed (was Centralized under CTO) (8-K, Apr 22 2026)
The board
Board of directors
4 directors. 3 of 4 independent (75%). Source: most recent DEF 14A.
Robert A. Bradway
Chair Inside
Chairman and CEO, Amgen Inc.
Robert A. Eckert
Lead Indep. Independent
Former Chairman and CEO, Mattel
Wanda M. Austin
Independent
Former President and CEO, The Aerospace Corporation
Greg C. Garland
Independent
Chairman and CEO, Phillips 66
The board, organized
Board committees
2 standing committees. Audit and Compensation must be 100% independent under SEC rules; the rest vary.
Audit Committee
100% independent
- Robert A. Eckert Chair
- Wanda M. Austin
Compensation and Management Development Committee
100% independent
Frequently Asked Questions
Who is the CEO of Amgen?
Robert A. Bradway has served as Chairman, CEO, and President of Amgen since 2011.
What type of organizational structure does Amgen use?
Amgen operates a divisional structure centered on R&D and global commercial operations, with strong functional oversight.
How many direct reports does Amgen's CEO have?
As of 2026, the CEO has five direct executive reports.
How has Amgen's leadership changed recently?
In April 2026, Amgen announced the retirement of its CTO and a redistribution of technology responsibilities across executives.
Does Amgen have a COO?
No. Amgen does not have a Chief Operating Officer; major functions report directly to the CEO.
Sources
- 8-K Filing, Apr 22, 2026
- Company 8-K, Apr 2026
- SEC EDGAR: Amgen Inc. DEF 14A Proxy Statement
- SEC EDGAR: Amgen Inc. 10-K Annual Report
Reference
Cite this page
If you reference this page in research, analysis, or news writing, use one of the formats below. Citation includes the SEC filing source where applicable.
APA 7th
Creately. (2026). Amgen Inc. organizational structure. Creately. Retrieved , from https://creately.com/org-chart/fortune-500/amgen/MLA 9th
"Amgen Inc. Organizational Structure." Creately, April 1, 2026, https://creately.com/org-chart/fortune-500/amgen/. Accessed .Chicago 17
Creately. "Amgen Inc. Organizational Structure." Last modified April 1, 2026. https://creately.com/org-chart/fortune-500/amgen/.Original SEC source View on SEC ↗
Amgen Inc.. DEF 14A. Filed 2026-04-07. U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/318154/000119312526145588/d13946ddef14a.htmPermanent URL: https://creately.com/org-chart/fortune-500/amgen/ · last updated 2026-04-01